Heterocyclic compound, organic light-emitting element comprising same, and composition for organic material layer
US-2024298525-A1 · Sep 5, 2024 · US
Furyl and thienyl triazole derivatives and therapeutic uses thereof
US9290484B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9290484-B2 |
| Application number | US-201313774231-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 22, 2013 |
| Priority date | Feb 22, 2013 |
| Publication date | Mar 22, 2016 |
| Grant date | Mar 22, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Nitric oxide biosynthesis-inhibiting anti-inflammatory and anti-microbial compounds of Formula (3) and Formula (4) wherein R1 and R2 are independently selected from optionally substituted thienyl, optionally substituted furyl, optionally substituted —CH═CH-thienyl and optionally substituted —CH═CH-furyl, provided that R2 is substituted with as nitro group Treatment methods utilizing the compounds, and methods of synthesis of the compounds are also disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of Formula (4): wherein R1 is thien-2-yl and R2 is 5-nitrothien-2-yl, or R1 is 4-hydroxyphenyl and R2 is 5-nitrothien-2-yl. 2. A pharmaceutical composition comprising at least one compound of claim 1 and at least one compound selected from the group of pharmaceutically acceptable adjuvants, carriers, diluents and excipients. 3. A topical pharmaceutical composition comprising the composition of claim 2 , wherein said at least one compound selected from the group of pharmaceutically acceptable adjuvants, carriers, diluents and excipients is adapted for topical application.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
1,2,4-Triazoles · CPC title
containing three or more hetero rings · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9290484B2 cover?
- Nitric oxide biosynthesis-inhibiting anti-inflammatory and anti-microbial compounds of Formula (3) and Formula (4) wherein R1 and R2 are independently selected from optionally substituted thienyl, optionally substituted furyl, optionally substituted —CH═CH-thienyl and optionally substituted —CH═CH-furyl, provided that R2 is substituted with as nitro group Treatment me…
- Who is the assignee on this patent?
- Univ New Jersey Med, Univ Rutgers, Univ Lehigh
- What technology area does this patent fall under?
- Primary CPC classification C07D409/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).